To determine whether CBP/P300 HAT activity is essential for leukemia cell maintenance, we utilized the selective acetyltransferase inhibitor A485. Mass spectrometry analysis of post-translational modifications showed that A485 treatment of K/C-III-expressing HEK293T cells for 6 and 12 hours significantly reduced multiple histone acetylation marks.